LONDON: The Covid-19 vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a “winning formula” for efficacy, the company’s chief executive said on Sunday.
- The vaccine, currently being evaluated by Britain’s independent medicines regulator, provides “100 percent protection” against severe Covid disease requiring hospitalisation, Pascal Soriot said in an interview with the Sunday Times newspaper.
- He added he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95 percent and Moderna at 94.5 percent.
- The Pfizer-BioNTech vaccine was the first coronavirus shot to be authorised for use by the UK’s independent medicines regulator and has been given to 600,000 of the country’s most vulnerable people since last month.
- Behind this average figure from large-scale trials in the UK and Brazil was a 62 percent effectiveness for those who were vaccinated with two full doses of the shot.
- For volunteers who received a half-dose first and then a full dose one month later, however, the vaccine was found to have 90 percent efficacy.
- Nearly 200 million doses of the AstraZeneca vaccine will be made before the end of the year, the UK drug manufacturer has said, and more than 700 million globally by the end of March next year.